Year: 2024

TORONTO, CANADA — (April 19, 2024) – Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSX: ATE) announced that the Company sought an extension of its previously announced stay of proceedings (“Stay”) under the Companies’ Creditors Arrangement Act (the “CCAA”) at a hearing before the Ontario Superior Court of Justice (Commercial List) (the “Court”) on April 18, … Continued

TORONTO, CANADA — (April 16, 2024) – Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSX: ATE) announced that the Toronto Stock Exchange (“TSX”) is reviewing the eligibility for continued listing on the TSX of the securities of the Company. The TSX has identified the Company’s financial condition as a criterion for delisting applicable to the Company. … Continued

TORONTO, CANADA — (April 9, 2024) – Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSX: ATE, OTCQX: ATBPF) announced that its previously announced application for an Initial Order under the Companies’ Creditors Arrangement Act (the “CCAA“), has been granted by the Ontario Superior Court of Justice (Commercial List) (the “Court“). Pursuant to the Initial Order, the … Continued

TORONTO, CANADA — (April 9, 2024) – Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSX: ATE, OTCQX: ATBPF) announced that it intends to file an application today with the Ontario Superior Court of Justice (Commercial List) (the “Court“) for an Initial Order under the Companies’ Creditors Arrangement Act (the “CCAA“). The application seeks an order that … Continued

TORONTO, CANADA — (April 1, 2024) – Antibe Therapeutics Inc. (“Antibe” or the “Company” TSX: ATE, OTCQX: ATBPF) today announced that it received verbal notice on the afternoon of March 28, 2024 from the U.S. Food and Drug Administration (“FDA”) that otenaproxesul has been placed on clinical hold, postponing the initiation of the planned Phase … Continued

– The American Society of Regional Anesthesia and Pain Medicine is the largest subspecialty medical society in anesthesiology TORONTO, CANADA — (March 20, 2024) – Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage biotechnology company leveraging its hydrogen sulfide platform to target pain and inflammation, is pleased to announce a moderated poster presentation of … Continued

– AAPM is the primary organization for pain medicine physicians in the U.S.  TORONTO, CANADA — (March 7, 2024) – Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage biotechnology company leveraging its hydrogen sulfide platform to target pain and inflammation, is pleased to announce a poster presentation of data from otenaproxesul’s recent pharmacokinetic/pharmacodynamic (“PK/PD”) … Continued

TORONTO, CANADA — (March 4, 2024) – Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage biotechnology company leveraging its hydrogen sulfide platform to target pain and inflammation, today announced that the arbitrator has found in favor of Nuance Pharma in the dispute regarding the license agreement for the commercialization of otenaproxesul in the Greater … Continued

– Successful PK/PD study confirms liver safety, sets stage for upgraded Phase II trial launch next month – Phase II trial enhancements include placebo arm, increased sample size and adaptive design – Ended quarter with $25 million in cash and equivalents  TORONTO, CANADA — (February 14, 2024) – Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), … Continued

TORONTO, ON – February 1, 2024 – Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, is extending the Early Warrant Exercise Incentive Program (“Early Warrant Exercise Program”) for its 6.4 million outstanding and unlisted share purchase warrants having an … Continued